RVPH — Reviva Pharmaceuticals Holdings Share News
0.000.00%
Last trade - 00:00Brief: Reviva Pharmaceuticals Holdings Inc - To Be Delisted From Nasdaq Trading Suspended As Of May 14, 2026 - SEC Filing
Brief: Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed
Reviva Pharma plunges on highly dilutive stock-and-warrants offering
Brief: Reviva Pharmaceuticals Announces Pricing Of $10 Million Public Offering At $1.50 Per Share
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Reviva Announces Publication On Clinical Vocal Biomarker Data From The Recover Phase 3 Clinical Trial Of Brilaroxazine
Brief: Reviva Announces Regulatory Update Regarding The Development Of Brilaroxazine For The Treatment Of Schizophrenia
Brief: Reviva Pharmaceuticals Recover-2 Trial Projected To Cost About $60 Million
Reviva Pharmaceuticals Q3 net loss narrows
Brief: Reviva Pharmaceuticals Q3 EPS USD -0.06
Brief: Reviva To Present Negative Symptom Data For Brilaroxazine In Schizophrenia From Phase 3 Trials At CNS Summit 2025